Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It has greater selectivity for vascular smooth muscle than for cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. It does not significantly affect sinoatrial nodal or atrioventricular conduction.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Short-term treatment of hypertension when oral therapy is not feasible or desirable (FDA approved),Prolonged treatment of hypertension in patients unable to take oral medications (off-label),Management of hypertensive emergencies (off-label),Subarachnoid hemorrhage (off-label),Prevention and treatment of cerebral vasospasm (off-label)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Administer intravenously at an initial rate of 5 mg/h, titrated by increasing by 2.5 mg/h every 5-15 minutes to a maximum of 15 mg/h for hypertension. For substitution of oral therapy, start at 0.5 mg/h and titrate to achieve desired blood pressure.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal elimination half-life is 8.6 hours (range 6-10 hours) in adults with normal hepatic function; prolonged in elderly or hepatic impairment. Clinical context: permits continuous IV infusion for stable hemodynamic control.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Primarily hepatic via cytochrome P450 isoenzymes CYP3A4 and CYP3A5, with minor contributions from CYP2C8. The drug undergoes extensive first-pass metabolism resulting in low oral bioavailability; however, intravenous administration bypasses first-pass metabolism. Metabolites are inactive and excreted primarily in urine (60%) and feces (35%).
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily hepatic metabolism (>90%) with <1% unchanged drug excreted renally. Fecal excretion accounts for approximately 35% of metabolites via biliary elimination.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
>95% bound to plasma proteins (primarily albumin, alpha-1-acid glycoprotein). High binding limits free drug concentration.
Low protein binding; 0–11% bound, primarily to albumin.
8.3 L/kg (0.08-0.17 L/kg in some sources; clinical meaning: extensive tissue distribution, particularly in vascular smooth muscle; Vd increases with hepatic impairment).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Oral: ~35% (first-pass effect); IV: 100% (not applicable for this formulation, but provided for context).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No specific dose adjustment required for renal impairment; however, use with caution if GFR <30 m L/min due to risk of accumulation of nicardipine metabolites.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
In patients with cirrhosis and clinically significant portal hypertension (Child-Pugh class B or C), reduce initial dose to 0.5 mg/h and titrate cautiously. Monitor for hypotension and bradycardia.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Not FDA-approved for pediatric use. Limited data: initial dose 0.5-1 mcg/kg/min continuous infusion, titrate up to 3-5 mcg/kg/min for hypertension.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Start at lower initial infusion rate (3 mg/h) and titrate slowly due to decreased clearance and increased sensitivity to hypotension. Monitor closely for adverse effects.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Use caution in patients with coronary artery disease: may increase frequency, duration, or severity of angina during initiation or upward titration.,Hypotension: monitor blood pressure closely; particularly in patients with reduced left ventricular function.,Hepatic impairment: reduced clearance; consider dose reduction and monitor liver function.,Renal impairment: may require dose adjustment; monitor renal function.,Ventricular ectopy and ventricular tachycardia have been reported, especially in patients with preexisting conduction abnormalities.,Avoid abrupt discontinuation; taper gradually to prevent rebound hypertension.,Use with beta-blockers: increased risk of heart failure; monitor cardiac function.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to nicardipine or any component of the formulation.,Severe hypotension (systolic blood pressure <90 mm Hg).,Cardiogenic shock or decompensated heart failure.,Advanced aortic stenosis (may reduce coronary perfusion).,Concurrent use with strong CYP3A4 inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole) requires caution; contraindicated if coadministration with certain strong inhibitors leads to severe hypotension.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Grapefruit and grapefruit juice are contraindicated as they increase nicardipine levels via CYP3A4 inhibition. High-fat meals may reduce absorption when taken orally, but IV route bypasses this. Avoid excessive sodium intake as it may counteract antihypertensive effects.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show teratogenicity (skeletal, cardiovascular) at high doses. Second/third trimesters: Risk of fetal hypoxia due to maternal hypotension; calcium channel blockers may inhibit uterine contractions. Use only if potential benefit outweighs risk.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE enters breast milk in low concentrations (M/P ratio approximately 0.7). No adverse effects reported in infants; however, caution advised. Monitor infant for hypotension, bradycardia.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Increased volume of distribution and clearance in pregnancy may necessitate higher doses; however, titration to effect is recommended due to hypotension risk. Start at low doses and increase gradually.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
For acute hypertension, administer as a continuous IV infusion (5 mg/hr, titrate up to 15 mg/hr). Monitor blood pressure every 5-15 minutes during titration. Use cautiously in advanced aortic stenosis; may precipitate angina. Extravasation can cause tissue necrosis; ensure central line access if peripheral infusion is prolonged. Nicardipine is photolabile; protect infusion bag from light and discard after 24 hours. In hepatic impairment or elderly, start at 3 mg/hr to avoid hypotension.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Report any chest pain, irregular heartbeat, or dizziness immediately.,Avoid sudden standing to prevent orthostatic hypotension.,This medication is given intravenously; you will be monitored closely.,Notify nurse if you experience pain, redness, or swelling at the IV site.,Do not eat grapefruit or drink grapefruit juice while on this medication.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Ximelagatran, a prodrug of the direct thrombin inhibitor melagatran, is primarily metabolized by CYP450 enzymes, particularly CYP2C9 and to a lesser extent CYP3A4. Nicardipine, a dihydropyridine calcium channel blocker, is extensively metabolized by CYP3A4. Coadministration of ximelagatran with nicardipine may result in inhibition of CYP3A4-mediated metabolism of nicardipine, leading to increased nicardipine plasma concentrations, enhanced hypotensive effects, and potentially elevated risk of adverse events such as edema, headache, and dizziness."
"Cinnarizine, a piperazine derivative with antihistaminic and calcium channel-blocking properties, inhibits cytochrome P450 (CYP) 3A4, the primary enzyme responsible for the metabolism of nicardipine, a dihydropyridine calcium channel blocker. This inhibition leads to reduced clearance and elevated plasma concentrations of nicardipine, potentially resulting in enhanced vasodilation, hypotension, reflex tachycardia, and increased risk of adverse effects such as peripheral edema, dizziness, and headache. Clinically, patients may experience exaggerated hypotensive responses and cardiovascular instability."
"Etoricoxib, a selective COX-2 inhibitor, can inhibit the metabolism of nicardipine, a dihydropyridine calcium channel blocker, via competitive inhibition of CYP3A4. This results in elevated plasma concentrations of nicardipine, potentially leading to enhanced hypotensive effects and an increased risk of adverse events such as dizziness, headache, peripheral edema, and reflex tachycardia. Clinically, this interaction may necessitate dose adjustment and careful monitoring of blood pressure and heart rate."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE is a Electrolyte that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It has greater selectivity for vascular smooth muscle than for cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. It does not significantly affect sinoatrial nodal or atrioventricular conduction.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE is: Administer intravenously at an initial rate of 5 mg/h, titrated by increasing by 2.5 mg/h every 5-15 minutes to a maximum of 15 mg/h for hypertension. For substitution of oral therapy, start at 0.5 mg/h and titrate to achieve desired blood pressure.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE is classified as Category A/B. Pregnancy Category C. First trimester: No adequate human studies; animal studies show teratogenicity (skeletal, cardiovascular) at high doses. Second/third trimesters: Risk of feta. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.